Pharmaceutical Technology on MSN
JPM26: BioNTech gears up for multiproduct oncology status by 2030
Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 ...
13d
BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan
BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to ...
BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief executive officer saying he would consider a deal with a partner that gets ...
JERUSALEM, Israel, and MAINZ, Germany, September 7, 2022 —BioNTech SE (BNTX) (Nasdaq: BNTX) announced today that Prof. Ugur Sahin, CEO and Co-founder of BioNTech (NTGN), visited Israel to meet with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results